Burcon Highlights Strong Year of Execution and Commercial Momentum in Shareholder Letter
Rhea-AI Summary
Burcon (OTCQB: BRCNF) issued a shareholder letter highlighting 2025 commercial progress and plans for 2026 growth. The company reports calendar 2025 revenue of $1–3 million, validated its patented protein technologies at full commercial scale, and is selling ingredients across pea, canola, and fava platforms. Management reaffirmed a 2026 revenue target of more than $10 million and described a near‑term financing expected to support customer onboarding, increase throughput, and strengthen the balance sheet.
Burcon cites a pipeline of 200+ customer projects, a strategic manufacturing partnership with RE ProMan LLC, and insider support for the financing as evidence of commercial momentum entering 2026.
Positive
- 2025 revenue expected at $1–3 million
- 2026 revenue target reaffirmed at >$10 million
- Patented proteins validated at full commercial scale
- Pipeline of 200+ new customer projects
Negative
- 2025 revenue remains modest at $1–3M versus a >$10M target for 2026
- Financing completion is pending and required to fund growth plans
- Execution depends on scaling via a single manufacturing partner
News Market Reaction
On the day this news was published, BRCNF gained 3.11%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Accelerating Demand Driving Strong Revenue Growth
Vancouver, British Columbia--(Newsfile Corp. - December 15, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein innovation, is pleased to issue a letter to shareholders from its Chief Executive Officer, Kip Underwood.
Dear Fellow Shareholders,
2025 was a transformational year for Burcon, marking the beginning of an exciting phase of growth as we build on our commercial momentum heading into 2026. I can say with confidence that Burcon has never been in a stronger position than it is today. Our achievements in commercial execution, manufacturing, and technology validation have positioned us for meaningful growth as we advance into the next phase of our commercialization journey.
Commercial Momentum and Sales Growth
In recent months, we have seen customers progress from evaluation to commercial purchase orders, driven by our clear product differentiation-high purity, clean taste, and functionality across multiple food and beverage applications.
Today, we are generating ingredient sales across our pea, canola, and fava protein platforms, with calendar 2025 revenue expected to be in the range of
Proven Protein Technology Platform
Through our strategic manufacturing partnership with RE ProMan LLC, we continue to advance the commercial deployment of Burcon's protein technology platform, enabling scalable, reliable production to meet growing customer demand across multiple protein categories.
A major achievement this year was the successful validation of our patented protein technologies at full commercial scale. This accomplishment significantly reduces technology and execution risk and confirms Burcon's ability to consistently deliver high-performance protein ingredients into large and rapidly expanding food and nutrition markets.
Industry Demand Aligned with Burcon's Strengths
Food and beverage manufacturers are increasingly looking for clean-label, better-tasting plant proteins. Burcon's ingredients offer high purity and performance, enabling manufacturers to deliver high-quality products that consumers will enjoy.
This alignment of market demand with our core strengths is driving the pipeline of 200+ new customer projects and driving the progression from evaluations into commercial ingredient sales.
Financial Readiness
Burcon is at an inflection point. To fully capitalize on this momentum, we are making targeted production investments to meet rising demand and support accelerated growth. Burcon is finalizing a financing, the proceeds of which are expected to:
- Support customer onboarding and accelerate conversion of ingredient sales
- Increase operational throughput as demand scales
- Strengthen balance sheet flexibility during our commercial expansion
The financing is strongly supported by insiders and by our manufacturing partner, reflecting confidence from those closest to our operations and strategy. Once completed, the financing is expected to strengthen our balance sheet to accelerate near-term growth initiatives and achieve positive cash flow.
The key objective of this financing is to accelerate our execution at a moment when Burcon is gaining commercial traction and revenue visibility.
Entering 2026 with Strong Momentum
Burcon enters 2026 with a strong foundation: proven technology, a scalable commercial facility, growing ingredient sales, and strengthening customer demand. Moreover, we have a clear line of sight to our revenue targets and confidence in our path toward achieving positive cash flow.
In closing, we expect 2026 to be a year of substantial growth for Burcon, and one in which we deliver meaningful value back to you, our shareholders. Thank you for your continued support and belief in our mission.
Sincerely,
"Kip Underwood"
Kip Underwood
Chief Executive Officer
About Burcon NutraScience Corporation
Burcon is a global technology leader in high-performance plant-based proteins for the food and beverage industry. Our commercial ingredients offer superior taste, texture, and functionality-ideal for formulators seeking next-generation protein solutions. Backed by over two decades of innovation, Burcon holds an extensive patent portfolio covering novel proteins derived from pea, canola, soy, hemp, sunflower, and other plant sources. As a key player in the rapidly growing plant-based market, Burcon is committed to sustainability and to creating best-in-class protein solutions that are better for people and the planet. Learn more at www.burcon.ca.
Forward-Looking Information Cautionary Statement
The TSX has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation, including statements relating to insider participation in the private placement. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements or forward-looking information can be identified by words such as "anticipate," "aim", "intend," "plan," "goal," "project," "estimate," "expect," "believe," "future," "likely," "may," "should," "could," "will" and similar references to future periods. All statements included in this release, other than statements of historical fact, are forward-looking statements. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon's plans and expectations include the implementation of our business model and growth strategies; trends and competition in our industry our future business development, financial condition and results of operations and our ability to obtain financing cost-effectively; potential changes of government regulations, and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled "Risk Factors" in Burcon's annual information form for the year ended March 31, 2025 and its other public filings with Canadian securities regulators on SEDAR+ at www.sedarplus.ca. This list is not exhaustive of the factors that may affect any of the Company's forward-looking statements or information. Any forward-looking statement or information speaks only as of the date on which it was made, and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and, accordingly, investors should not rely on such statements.
Industry and Investor Contact
Paul Lam
Director, Investor Relations and Communications
Burcon NutraScience Corporation
490 - 999 West Broadway, Vancouver, BC, V5Z 1K5
Tel (604) 733-0896, Toll-free (888) 408-7960
plam@burcon.ca www.burcon.ca
Media Contact:
Steve Campbell, APR
President
Campbell & Company Public Relations
Tel (604) 888-5267
TECH@CCOM-PR.COM
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/278025
FAQ
What revenue did Burcon (BRCNF) report for calendar 2025 and what is the 2026 target?
How did Burcon validate its protein technologies for commercial production?
What is the size of Burcon's customer pipeline mentioned in the shareholder letter?
What is the purpose of the financing Burcon is finalizing and who supports it?
Which protein platforms is Burcon currently generating ingredient sales from?
What manufacturing partner is helping Burcon scale production for commercial demand?
